<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269281</url>
  </required_header>
  <id_info>
    <org_study_id>BA0559019</org_study_id>
    <nct_id>NCT01269281</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions</brief_title>
  <official_title>Open Label, Randomized, Two Way Crossover, Comparative Evaluation of Relative Bioavailabilities of Two Formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories Limited, India)With the Reference Formulation Imitrex Tablets 100 mg (Glaxosmilthkine) in Healthy Adult Subjects Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the relative bioavailability of Sumatriptan
      Succinate Tablets 100 mg with Imitrex Tablets 100 mg under fed conditions in healthy adult
      human subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open Label, Randomized, Two way crossover, comparative evaluation of relative bioavailability
      of two formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories
      Limited, India) With the Reference Formulation ImitrexÂ® 100 mg Tablet (Glaxosmithkline,
      USA)Under Fed Conditions in Healthy Human Adult Subjects. 50 healthy, adult, human male
      subjects were enrolled in the study and 43 subjects are completed the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUCt and AUCi parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sumatriptan Succinate tablets 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imitrex 100 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imitrex 100 mg Tablets of Glaxosmithkline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Sumatriptan Succinate Tablets 100 mg</description>
    <arm_group_label>Sumatriptan Succinate tablets 100 mg</arm_group_label>
    <arm_group_label>Imitrex 100 mg Tablets</arm_group_label>
    <other_name>Imitrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects should be healthy males between 18 and 45 years.

          2. The subjects should be screened within 21 days prior to the administration of first
             dose of the study..

          3. The subjects should have a BMI between 18 and 25 kg/m2

          4. The subjects should be able to communicate effectively with study personnel

          5. The subjects should be literate and able to give consent

          6. If subject is a female volunteer and

               -  Is of child bearing potential practicing an acceptable method of birth control
                  for the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device(IUD), or abstinence

               -  Is postmenopausal for at least 1 year

               -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject).

        Exclusion Criteria:

          1. The subjects who have a history of allergic responses to Sumatriptan or other related
             drugs

          2. The subjects who have history of intake of MAOI within two weeks of dosing

          3. The subjects who have history of drug dependence, recent history of alcoholism or of
             moderate alcohol uses..

          4. The subjects who have significant diseases or clinically significant abnormal findings
             during screening, medical history, physical examination, laboratory evaluations, ECG,
             and X-ray recordings..

          5. The subjects who have any disease or condition which might compromise the
             haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central
             nervous system, diabetes, psychosis or glaucoma or any other body system.

          6. The subjects who have a history or presence of asthma (including aspirin induced
             asthma) or nasal polyp..

          7. The subjects who are smokers and who smoke more than 10 cigarettes/day or those who
             cannot refrain from smoking during study period..

          8. The subjects with a history of difficulty with donating blood or difficulty in
             accessibility of veins..

          9. The subjects who have donated 01 unit (350 ml / 450 ml) blood within 90 days prior to
             receiving the first dose of study medication (if blood loss is below or equal to
             200mL, subjects can be enrolled in the trial after 60 days of donation).

         10. The subject who has a positive hepatitis screen including hepatitis B surface antigen,
             anti HCV, anti HEV.

         11. The subject who has a positive test result for HIV antibody and / or syphilis
             (RPR/VDRL).

         12. The subject who receives an investigational product, or has participated in a drug
             research study within a period of 90 days prior to the first dose of the study
             medication administration (elimination half-life of study drug should be taken into
             consideration for inclusion of subject in the trial if blood loss is below or equal to
             200 mL).

         13. An unusual diet, for whatever reason (e .g. low sodium) for four weeks prior to
             receiving the study medication and throughout the subject's participation in the
             study.

         14. Female volunteers demonstrating a positive pregnancy screen.

         15. Female volunteers who are currently breast- feeding.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roma Choudhury, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Limited</name>
      <address>
        <city>Bodakdev</city>
        <state>Ahmedabad</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>General Manager - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>two way crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

